Trial Profile
A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Erlotinib; Gefitinib
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms FLAURA
- Sponsors AstraZeneca
- 15 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 07 Dec 2023 This trial has been completed in Poland, according to the European Clinical Trials Database record.
- 27 Nov 2023 Results of exploratory, post-hoc analysis aimed to model circulating tumor ct DNA dynamics and predict disease progression , published in the Clinical Pharmacology and Therapeutics